Ultra-effective near-infrared Photothermal therapy for the prostate cancer Nursing care through novel intended and surface tailored photo-responsive Ga-Au@MPS nanovesicles

In this study, we used GaAu loaded mesoporous silica nanoparticles (Ga-Au@mSiO2) for the photothermal treatment of two prostate cancer cell lines. We systematically examined the nanocomposite form by various spectroscopic (UV–Vis, TGA and DTA) and electroscopic techniques (TEM and SEM including the elemental mapping analysis). After careful evaluation of the nanocomposite form, we performed cancer cell growth inhibition properties of the prostate cancer cell lines (DU145 and LNCaP). Also, we performed the photothermal effects of these nanocomposites on cell proliferation and apoptosis using different biochemical staining and flow cytometry. Our in vitro investigational datas are established Ga-Au@mSiO2 effectively exhibited and also with Ga-Au@mSiO2 + NIR the photothermal conversion therapy improved prostate cancer cells abolishing the prostate cancer cells. Interestingly, Ga-Au@mSiO2 + NIR was found to surpass the activity of Ga-Au@mSiO2 in all the cancer cells tested a topnotches. Hence, our current results demonstrated that surface tailored GaAu loaded mesoporous silica nanoparticles significantly inhibited the growth of prostate cancer cell lines and shown prominent antitumor effect in vitro. Thus, our study suggests that Ga-Au@mSiO2 + NIR could be used as impending anticancer candidate for photothermal ablation of prostate cancer cells. Further examinations of the mechanism indicated that anticancer activity was accomplished by inducing apoptosis in can...
Source: Journal of Photochemistry and Photobiology B: Biology - Category: Speech-Language Pathology Source Type: research

Related Links:

Selenium deficiency is associated with many physiological disorders including the high risk of cancer. The rehabilitation of selenium with different selenium supplements, however, fails due to their low therapeutic index. Therefore, it is advantageous to have a less toxic form of selenium for supplementation with potentially high anticancer activity. Here we show Bacillus licheniformis derived biogenic selenium nanoparticles at a minimal concentration of 2 μg Se/ml induce necroptosis in LNCaP-FGC cells, without affecting the RBC integrity. Real-time gene expression analysis indicated the overexpression of tumor necrotic...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsAdditional research is needed to examine the efficacy of consumer wearable devices in promoting physical activity and weight management among cancer survivors.Implications for Cancer SurvivorsCancer survivors show an increase in physical activity when using consumer wearable activity trackers. Increased physical activity plays an important role in alleviating many adverse effects of breast cancer therapy as well as improving morbidity and mortality. Additional research such as clinical trials focused on the development of successful interventions utilizing these devices is warranted.
Source: Journal of Cancer Survivorship - Category: Cancer & Oncology Source Type: research
NCI ’ s Center for Cancer Research (CCR) Grand Rounds Dr. Pienta is a Professor of Urology, Oncology, Pharmacology and Molecular Sciences and Chemical and Biomolecular Engineering as well an American Cancer Society Clinical Research Professor. Between 1995 and 2013, Dr. Pienta served as the Director of the Prostate Specialized Program of Research Excellence (SPORE) at the University of Michigan and has served as co-PI of the Johns Hopkins Prostate SPORE from 2013-2018. He has a proven, peer-reviewed track record in organizing and administering a translational research program that successfully incorporates bench rese...
Source: Videocast - All Events - Category: General Medicine Tags: Upcoming Events Source Type: video
Authors: Yeh Y, Guo Q, Connelly Z, Cheng S, Yang S, Prieto-Dominguez N, Yu X Abstract Metastatic or locally advanced prostate cancer (PCa) is typically treated with androgen deprivation therapy (ADT). Initially, PCa responds to the treatment and regresses. However, PCa almost always develops resistance to androgen deprivation and progresses to castrate-resistant prostate cancer (CRPCa), a currently incurable form of PCa. Wnt/β-Catenin signaling is frequently activated in late stage PCa and contributes to the development of therapy resistance. Although activating mutations in the Wnt/β-Catenin pathway are ...
Source: Advances in Experimental Medicine and Biology - Category: Research Tags: Adv Exp Med Biol Source Type: research
Authors: Storbeck KH, Mostaghel EA Abstract Androgens are critical drivers of prostate cancer. In this chapter we first discuss the canonical pathways of androgen metabolism and their alterations in prostate cancer progression, including the classical, backdoor and 5α-dione pathways, the role of pre-receptor DHT metabolism, and recent findings on oncogenic splicing of steroidogenic enzymes. Next, we discuss the activity and metabolism of non-canonical 11-oxygenated androgens that can activate wild-type AR and are less susceptible to glucuronidation and inactivation than the canonical androgens, thereby servin...
Source: Advances in Experimental Medicine and Biology - Category: Research Tags: Adv Exp Med Biol Source Type: research
Authors: Mabonga L, Kappo AP Abstract Small nuclear ribonucleoprotein polypeptide G (SNRPG), often referred to as Smith protein G (SmG), is an indispensable component in the biogenesis of spliceosomal uridyl-rich small nuclear ribonucleoprotein particles (U snRNPs; U1, U2, U4 and U5), which are precursors of both the major and minor spliceosome. SNRPG has attracted significant attention because of its implicated roles in tumorigenesis and tumor development. Suggestive evidence of its varying expression levels has been reported in different types of cancers, which include breast cancer, lung cancer, prostate cancer ...
Source: American Journal of Translational Research - Category: Research Tags: Am J Transl Res Source Type: research
Healthcare insurance companies should value PET imaging and its cost-effective...Read more on AuntMinnie.comRelated Reading: CMS final rule for MPFS could cost radiology $5B CMS gets pushback on PET fee cuts PSMA-PET/CT most effective for recurrent prostate cancer Editorial slams NRC plan to expand radiopharmaceutical users PET tracers help guide breast cancer therapies
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
In this study, prodrug candidates (1-36) containing nitro were designed, synthesized and characterized within the scope of chemical experiments. Drug-likeness properties of prodrug candidates were analyzed using DS 2018 to investigate undesired toxicity effects. In vitro cytotoxic effects of prodrug canditates were performed with MTT assay for human hepatoma cells (Hep3B) and prostate cancer cells (PC3) and human umbilical vein endothelial cells (HUVEC) as healthy control. Non-toxic compounds (3, 5, 7, 10, 12, 15, 17, 19 and 21-23), and also compounds (1, 2, 5, 6, 9, 11, 14, 16, 20 and 24) which had low toxic effects,...
Source: European Journal of Medicinal Chemistry - Category: Chemistry Authors: Tags: Eur J Med Chem Source Type: research
AbstractIntroductionThe present study aimed to indirectly compare apalutamide and enzalutamide with respect to tolerability and health-related quality of life (HRQoL) among men with non-metastatic castration-resistant prostate cancer (nmCRPC).MethodsPatient-level data from the SPARTAN study [apalutamide  + androgen deprivation therapy (ADT) versus placebo + ADT] and aggregate published data from the PROSPER study (enzalutamide + ADT versus placebo + ADT) were used. Anchored matching-adjusted indirect comparison (MAIC) was conducted by weighting patients’ baselin...
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
Mutational inactivation of p53 is a key player in the development of human cancer. Thus, retrieving the tumor suppressor activity of p53 gene is considered a novel strategy in cancer therapy. Current study aimed to investigate the anti-cancer potentials of botulinum toxin type-A (BTX-A) and captopril as a trial to shed light on effective anti-cancer therapy with lower side effects. Cytotoxic effect of captopril and BTX-A was determined using MTT assay against colon (HCT116) and prostate cancer (DU145) cells compared to their effect on normal vero cells. Anti-proliferation assay and anti-metastatic effect were carried out u...
Source: Iranian Journal of Pharmaceutical Research - Category: Drugs & Pharmacology Source Type: research
More News: Biology | Cancer | Cancer & Oncology | Cancer Therapy | Nanotechnology | Nurses | Nursing | Prostate Cancer | Speech-Language Pathology | Study